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Abstract
Urinary bladder cancer (UBC) ranks ninth in worldwide cancer. In Egypt, the pattern of bladder cancer is unique in that both
the transitional and squamous cell types prevail. Despite much research on the topic, it is still difficult to predict tumor
progression, optimal therapy and clinical outcome. The reduced folate carrier (RFC/SLC19A1) is the major transport system
for folates in mammalian cells and tissues. RFC is also the primary means of cellular uptake for antifolate cancer
chemotherapeutic drugs, however, membrane transport of antifolates by RFC is considered as limiting to antitumor activity.
The purpose of this study was to compare the mRNA expression level of RFC/SLC19A1 in urothelial and non-urothelial
variants of bladder carcinomas. Quantification of RFC mRNA in the mucosa of 41 untreated bladder cancer patients was
performed using RT-qPCR. RFC mRNA steady-state levels were ,9-fold higher (N=39; P,0.0001) in bladder tumor
specimens relative to normal bladder mRNA. RFC upregulation was strongly correlated with tumor type (urothelial vs. non-
urothelial; p,0.05) where median RFC mRNA expression was significantly (p,0.05) higher in the urothelial (,14-fold)
compared to the non-urothelial (,4-fold) variant. This may account for the variation in response to antifolate-containing
regimens used in the treatment of either type. RFC mRNA levels were not associated with tumor grade (I, II and III) or stage
(muscle-invasive vs. non-muscle invasive) implying that RFC cannot be used for prognostic purposes in bladder carcinomas
and its increased expression is an early event in human bladder tumors pathogenesis. Further, RFC can be considered as a
potential marker for predicting response to antifolate chemotherapy in urothelial carcinomas.
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Introduction
20–60% of the cancer incidence worldwide has been associated
with nutritional factors [1]. Among the most extensively studied
nutrients involved in cancer etiology is the vitamin folic acid.
Folates are essential for life, and folate deficiency contributes to a
host of health problems including cardiovascular disease, fetal
abnormalities, neurological disorders, and cancer [1,2].
Cancer of the bladder is the ninth most common cancer
worldwide. The majority (77%) of bladder tumors occur in men. It
is the seventh most common malignancy in men and 17th in
women [3]. The spectrum of bladder tumors is broad and includes
transitional cell carcinoma (TCC), squamous cell carcinoma
(SCC), adenocarcinoma and small cell carcinoma. TCC is by far
the most prevalent and best studied. In the United States, 90% of
bladder tumors are of the urothelial variant that evolves from
transitional cells. Conversely, in Egypt, the most common
histopathological type of bladder cancer used to be SCC [4],
constituting from 59% to 81% of reported bladder cancers
between 1960 and 1980 [4,5]. Contrary to the leading etiology of
smoking and occupational exposures in Western countries, chronic
bladder infection with Schistosoma haematobium, has been the most
important risk factor for bladder cancer in Egypt [5]. However,
recent studies [5,6] reported that SCC in Egypt appears to have
decreased from 78% in 1980 to 27% in 2005.
Biopsy samples of the bladder tumor lesions can be easily
obtained by trans-urethral resection (TUR) prior to treatment.
Despite much research on the topic, it is still difficult to predict
tumor progression, optimal therapy and clinical outcome [7].
Tumorstaging(TNMsystem)isconsideredtobe the best prognostic
marker; however, failure to accurately predict progression or
recurrence is often experienced [8]. In addition, treatment failure is
a major area in which translational bladder cancer research could
benefit patients. For instance, the MVAC regimen (an antifolate-
containing regimen) exhibits only limited antitumor activity against
non-transitional cell cancer while response rates up to ,70% were
reported in TCC in the same study [9]. If genetic discrepancies
between the two variants of bladder carcinomas affect their
progression and/or response to chemotherapy, then the question
is; which genetic marker(s) is (are) the most critical ones?
The ubiquitously expressed reduced folate carrier (RFC) is
considered the major transport route for folates at physiological
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present [1,10,11]. Loss of RFC expression or function portends
potentially profound physiological and developmental conse-
quences [1,12]. RFC is also a major transporter of antifolate
drugs used for cancer chemotherapy such as methotrexate (MTX),
pemetrexed, and raltitrexed. The effectiveness of chemotherapy
with these agents is closely linked to levels and activity of RFC in
both tumors and normal tissues [13,14]. MTX, for instance,
continues to be an important component of the chemotherapeutic
armamentarium for a variety of malignancies including bladder
cancer [15,16]. Pemetrexed has also been recently considered for
use in treatment of bladder cancer [16]. Membrane transport of
these antifolates is critical to antitumor activity since this provides
sufficient (unbound) intracellular drug to sustain maximal
inhibition of enzyme targets (e.g., DHFR; Dihydrofolate reduc-
tase) and for synthesis of polyglutamate derivatives required for
high affinity binding to intracellular enzymes [13]. The reduced
folate carrier gene expression can be reliably studied at the mRNA
level, and based on a number of studies [13,14,17,18,19,20,21] the
expression is likely to reflect the activity of the RFC in both tumors
and normal tissues. Hence, inspecting discrepancies in RFC
expression among the different types of bladder cancers may pave
the way for possible improvement of rationally based antifolate-
containing chemotherapy.
The present study was, thus, undertaken to investigate mRNA
expression and potential clinical relevance (i.e. associations with
tumor stage, grade and/or histological type) of the major folate
transporter, RFC, in a group of human urinary bladder tumors of
different histological types.
Materials and Methods
Ethical statement
An initial number of 61 bladder cancer patients were included
in this study. All patients’ data were analysed anonymously and
patients’ consent had been obtained to include excised tissue for
the current study via the pathology department at the National
Cancer Institute (NCI), Cairo, Egypt. All research protocols were
approved by the institutional review boards of the NCI and the
Research Ethics Committee of the German University in Cairo.
Patients
Sixty one tumor biopsies were obtained by TUR at the NCI
during the period from March 2009 to January 2010. 17
specimens were later excluded from the study during the RNA
quality check step (see below). For the remaining 44 specimens,
tumor stage and grade were assigned according to the TNM [4] by
the pathology unit at the NCI.. Patients included in this study
(n=44; 31 males , 11 females and 2 unidentified; age range: 31 to
79) were allocated into two main groups depending on tumor
histological type: urothelial tumors’ group; TCC and TCC with
squamous metaplasia; and non-urothelial tumors’ group; SCC and
adenocarcinoma. At the time of inclusion, none of the patients had
received treatment in any form. Clinical characteristics of the
bladder cancer patients included in this study are listed in
Table S1.
Total RNA extraction and reverse transcription
Excised tumor biopsies used for mRNA analysis were
immediately placed in RNAlaterH RNA Stabilization Reagent
(Qiagen, Germany), kept at 24uC overnight then stored at
220uC. Total RNA was extracted from frozen biopsies (,30 mg)
using Absolutely RNA mini-prep kit (Stratagene, Germany)
according to the manufacturers’ instructions. Isolated RNA
integrity was electrophoretically verified by ethidium bromide
staining and by A260/A280 absorption ratio (range 1.8–2.0) (A260
nm=1 corresponds to 40 mg/ml RNA). A 2:1 intensity ratio
between 28S and 18S rRNA was considered a benchmark for
intact RNA (Figure S1). 17 tumor specimens were excluded from
the study based on their RNA integrity profile (Figure S1). 5 mg
total RNA was reverse transcribed with Sprint
TM RT Complete
Products kit (Clonetech, Germany) in a volume of 20 ml according
to the manufacturers’ instructions.
RT-qPCR quantification of RFC mRNA
The RT-qPCR protocol followed in this study was structured
around the Minimum Information for Publication of Quantitative
Real-Time PCR Experiments (MIQE) guidelines, published by
Bustin et al. [22]. RFC mRNA was quantified by RT-qPCR on
Mx3005P
TM instrument (Stratagene, USA). Transcripts of b-actin
were quantified as an endogenous RNA control [7,23] to eliminate
variations in the amount and/or quality of total RNA added to
each reaction mix and each sample was normalised on the basis of
its b-actin mRNA content. All the quantifications in this study are
presented as the ratio between the target gene and b-actin. Primer
sequences, annealing temperature and PCR products size for the
target gene RFC and the reference gene b-actin are presented in
Table 1. The specificity of each primer pair was confirmed by
melting curve analysis (Figure S2) which resulted in single product
specific melting temperatures.
Each primer pair was evaluated for secondary structures and
SNPs by the in silico evaluation tool at RTPrimerDB (http://
medgen.ugent.be/rtprimerdb). Highly purified salt-free primer for
RFC and b-actin (Table 1) were generated commercially
(Metabion GmbH, Germany) and optimised to a two-step
(combined annealing/extension temperature) PCR protocol. A
pool of 3 bladder cancer cDNA samples was used for assay
optimization and amplification efficiency evaluation (Table 1)
using ‘‘the standard curve’’ method. A standard curve for each
gene was then generated automatically by the Mx3005P
TM
software where log the target concentration was plotted against
the corresponding quantification cycle (Cq) value [22]. Conditions
for all PCRs were optimised with regard to forward and reverse
primers concentrations and various annealing temperatures (55–
66uC). Real-time PCR mastermix of the following reaction
components was prepared to the indicated end-concentration:
12.5 ml Power SYBRH Green PCR Master Mix (Applied
Biosystems, UK), 0.2 ml forward primer RFC (100 nM), 0.2 ml
reverse primer RFC (100 nM) and 11.1 ml nuclease-free water for
the target gene; and 12.5 ml Power SYBRH Green PCR Master
Mix, 0.75 ml forward primer b-actin (300 nM), 0.75 ml reverse
primer b-actin (300 nM) and 10 ml nuclease-free water for the
reference gene. 24 ml of the prepared mastermix were pipetted per
well in a 96-well plate. 1 ml cDNA template was then added to
each reaction well. Applications of total cDNA input were
performed in duplicates. The 96-well plate was sealed by a PCR
optical adhesive film (Eppendorf AG, Germany). The following
optimized thermal profile was used: denaturation program (95uC
for 10 min), amplification and quantification program repeated 40
times (95uC for 15 s, 60uC for 1 min, with a single fluorescence
measurement), melting curve program (55–95uC with a heating
rate of 0.1uC per second and a continuous fluorescence
measurement). The fluorescence data were collected and the
mRNA quantified with Mx3005P
TM software version 4.1. Cq
values were automatically calculated according to the ‘‘fit point
method’’; where Cq is defined as fractional number of cycles at
which the PCR kinetic curve reaches a program-defined threshold
amount of fluorescence.
RFC Expression in Bladder Cancer
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according to the method of Schmittgen and Livak [24]. As shown
in Table 2, the variation in b-actin expression was minimal among
the urothelial and non-urothelial groups.
Statistical Analysis
The data were tested for normality using the Shapiro-Wilk
normality test. Nonparametric tests were decided accordingly. P-
values less than 0.05 were considered to be significant. The Mann–
Whitney U-test and Kruskal–Wallis test were used to correlate the
expression of the RFC with tumor stage, grade and type. The
software Graph Pad Prism (version 5) was used for statistical analysis.
Results
mRNA expression of RFC
The mRNA expression of the folate transporter RFC was
quantified in 41 bladder cancer specimens, three specimens with
no evidence of malignancy obtained from bladder mucosa
adjacent to cancerous tissue, and a commercially available
reference bladder RNA pooled from 26 male/female Caucasians;
aged 22–70 (Clonetech, Germany). The latter will be referred to as
the calibrator in the following sections.
RFC mRNA expression was detected in all bladder specimens
used in this study. The steady-state expression levels of RFC
mRNA were significantly (P,0.0001) higher in the bladder cancer
specimens by ,9-fold (8.661, range 0.98–50, N=39) than in the
calibrator.
Clinical vs. hisotpathological parameters
A multivariate analysis was done to determine the most
significant factors with which RFC mRNA expression was
associated. The correlation between RFC mRNA levels and the
tested clinicopathological parameters of bladder cancer are
summarised in Table 3. RFC relative expression level was
significantly (P,0.05) higher in urothelial vs. non-urothelial
bladder carcinomas where RFC mRNA was increased by ,14-
fold (13.27; n=27) in urothelial tumors in comparison to 4-fold
(4.083; n=10) increase only in the non-urothelial variants
(Figure 1A). The median expression level of RFC in the TCC
specimens was 17.48; n=23 in comparison to 5.538; n=6 in
specimens classified as TCC with squamous metaplasia or mixed
transitional and squamous cell carcinomas. However, no statisti-
cally significant difference was found between RFC mRNA
expression in bladder cancer specimens classified as pure TCC
vs. those having TCC with squamous cell metaplasia (Figure 1D).
This shows that RFC mRNA expression in non-urothelial tumors
is much lower than in their urothelial counterparts and the
squamous component is predominantly associated with reduced
RFC mRNA expression. The expression level of RFC in bladder
cancer specimens containing bilharzial ova was compared to those
with no evidence of bilharzial infection where RFC mRNA was
significantly (P,0.05) decreased in bilharzial-associated (BA)
bladder cancer specimens (3.13; n=7) in comparison with the
non-bilharzial-associated group (9.76; n=32) (Figure 1E).
We examined the correlation between levels of expression of
RFC mRNA and markers of tumor aggressiveness (namely; grade
and stage). The expression of RFC mRNA didn’t correlate with
tumor grade (Figure 1B) where there was no statistically significant
difference (P=0.3008) detected between grades I, II, or III.
Further, RFC expression was not statistically altered (P=0.2666)
between muscle-invasive and non-muscle invasive specimens
(Figure 1C). Notably, all SCC specimens (n=8) were classified
as muscle-invasive tumors, which points to the more aggressive
nature of SCC and non-urothelial carcinomas. In addition, no
statistically significant difference (P=0.2162) was found between
the ages of patients with urothelial carcinomas (mean=60.42) vs.
those of the non-urothelial group (mean=52.88).
Discussion
Since mammalian cells cannot synthesize folates de novo, tightly
regulated cellular uptake processes have evolved to sustain
sufficient levels of intracellular folates [25,26]. In context of
malignancy, the major folate transporter system, RFC, increased
expression is consistent with the need to increase cellular retention
of folates to support the requirements of the rapidly dividing
cancer cells for DNA synthesis and replication. In the present
study, our findings in human bladder cancer biopsies were in
accordance with this notion where RFC mRNA expression was
significantly increased by ,14-fold in urothelial bladder carcino-
mas (TCC and TCC with squamous metaplasia) and by ,4-fold
in the non-urothelial variants (SCC & Adenocarcinoma). Altered
expression of RFC has been also reported in leukemias,
particularly B-precursor ALL [11,26,27], osteosarcoma [17],
colorectal cancer and primary central nervous system lymphomas
[1] at both the transcript and protein levels.
The discrepancy in RFC mRNA expression between urothelial
and non-urothelial bladder tumors, reported in the current study,
Table 1. Characterisitcs of gene-specific real-time PCR assays.
Gene/Accession No. Mer Amplicon Efficiency(%) Conc. Resources
SLC19A1 [GenBank:NM_194255.1] Primer ExpressH
FWD: CCT CGT GTG CTA CCT TTG CTT 21 125 105.8 100 nM
REV: TGA TCT CGT TCG TGA CCT GCT 21 100 nM
ACTB [GenBank:NM_001101.1] Ohl et al. [23]
FWD: AGC CTC GCC TTT GCC GA 17 174 93 300 nM
REV: CTG GTG CCT GGG GCG 15 300 nM
doi:10.1371/journal.pone.0021820.t001
Table 2. Fold change in the reference versus target genes
expression levels among the different histological subtypes of
bladder cancer.
Compared Groups b-actin fold difference RFC fold difference
Urothelial: non-urothelial 1.49 7.93
doi:10.1371/journal.pone.0021820.t002
RFC Expression in Bladder Cancer
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each type, which may affect transcriptional regulation of the
transporter. Both ubiquitous and tissue-specific TFs that transac-
tivate or repress transcription in response to requirements for
folate cofactors control the net levels of RFC transcripts in tissues
[1,18]. Literature and pathway mining using the LitInspector
software [28] showed that RFC (SLC19A1) has potential
interactions with CREB1 (CAMP responsive element binding
protein-1). CRE/ AP-1-like consensus sequence is one of the two
major sites of regulation of the RFC basal promoters [18]. CREB,
which binds to the CRE/AP-1, is among the TFs activated by the
ERKs (MAPK), which are components of the RTK-RAS signaling
pathway. Accruing evidence indicates that key components of this
signaling pathway are frequently activated in human urothelial
carcinomas [29], but not in the non-urothelial types [30,31]. In
human fibrosarcoma cells, CREB-1 and c-Jun were the cell-
specific transcription factors involved in CRE binding in the RFC
promoter. Similar findings were reported for CREB-1 and ATF-1
in human hepatocellular carcinoma cells and human leukemia
cells [18,32]. Furthermore, two thirds of the antifolate-resistant cell
lines displayed a marked decrease in transcription factor binding
to a single CRE site present in the minimal promoter A of the
RFC gene [33]. Hence, there is increasing evidence to suggest that
binding of CREB-1 to CRE in the RFC promoter is an important
contributor to the induction of RFC gene expression in cancer cell
lines and malignant tumors [18,32,33]. Therefore, we hypothesize
that the constitutive activation of the RTK–RAS pathway is
probably one factor that accounts for increased RFC mRNA
expression in urothelial carcinomas. In non-urothelial carcinomas,
however, RAS mutations are infrequent and other mutations
come into play (p16 & p15 deletion [31,32], Bax, Bak & EGFR
overexpression and p53 inactivation [32]). Hence, we expect
different genetic events to have led to the modest increase in RFC
Figure 1. mRNA expression of RFC in 39 human biopsy samples relative to the calibrator (A–E). Solid horizontal lines demonstrate the
median of each individual group. All data are shown as the ratio between the target gene and beta-actin. *P-value, non-parametric, Mann-Whitney or
Kruskal-Wallis tests. BA, Bilharizal-associated.
doi:10.1371/journal.pone.0021820.g001
Table 3. Correlation between RFC mRNA levels and
clinicopathological parameters of bladder cancer.
Tumor type
a Grade
b Stage
c Bilharziasis
d
Median RFC mRNA
expression relative
to the calibrator
P,0.05
e ns ns P,0.05
aUrothelial vs. non-urothelial.
bI vs. II vs. III.
cMuscle-invasive vs. non-muscle invasive.
dBilharzial-associated vs. non-bilharizal-associated bladder tumor.
eP-values (Mann-Whitney and Kurskal-Wallis tests); NS, not significant.
doi:10.1371/journal.pone.0021820.t003
RFC Expression in Bladder Cancer
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TFs involved in RFC transcription activation. This is further
supported by the fact that increased RFC expression is very likely
to be associated with inactivation of tumor suppressor genes,
where 5-Methyl tetrahydrofolate (5-CH3-THF) is a cofactor in the
de novo synthesis of S-adenosylmethionine that participates in
methylation of CpG islands. RFC is the main entry route for THF
and increased RFC expression would accordingly lead to
accumulation of the methylated reduced folate [11,15] which
may eventually lead to the inactivation of various tumor
suppressor genes like; p16, p15 and/or p53 [34,35].
Further, based on our present findings, RFC overexpression
implies that urothelial bladder carcinomas would be intrinsically
more sensitive to antifolates whereas non-urothelial carcinomas
would show a less favorable response to antifolate chemotherapy.
This speculation may explain why the MVAC regimen exhibits
only limited antitumor activity against non-transitional cell cancer
while response rates up to ,70% were reported in TCC in the
same study [9].
Our findings showing that RFC mRNA increased expression is
not associated with tumor grade or stage implicate that increased
expression of RFC mRNA seems to happen early in the process of
multi-step tumor progression. This hypothesis is further supported
by consistent RFC mRNA expression increase among the different
age groups in our study. However, it has been reported that only
,15% of the low-grade superficial tumors will proceed to infiltrate
the musculature and that high-grade muscle-invasive tumors,
either originate from flat carcinoma in situ (CIS)/severe dysplasia
or arise de novo [29]. Accordingly, an alternative hypothesis could
be that increased RFC mRNA expression occurs as a consequence
of independent events among the different types of bladder
carcinomas. Interestingly, all non-urothelial tumor biopsies
utilized in this study were muscle-invasive pointing to the
unfavorable diagnostic features of non-urothelial tumors as was
already suggested by Erdemir et al. [19]. The clinical significance
of squamous differentiation seems to be an unfavorable prognostic
feature due to its association with high grade invasive tumors.
Although a significant difference was detected between RFC
expression levels in bilharzial- and non-bilharzial-associated bladder
cancers, this finding cannot be conclusive since only 7 cases (18% of
total) of bilharzial-associated bladder cancer were included in this
study(c.f.32non-bilharzial-associatedcase).Further,thehigherlevel
of RFC mRNA expression in BA-TCC (2 specimens) versus the SCC
or mixed types (5 specimens) may also imply that RFC increased
mRNA expression is actually independent from bilharzial infection.
Worth mentioning (since this supports the relevance) is that the
characteristics of the bladder cancer specimens utilized in this
study were representative of bladder cancer patients’ population
with regards to gender, age and histological types. The ratio of
female:male patients was ,1:3. The mean age of all bladder
cancer patients included in the study was 60, where the mean age
of the non-urothelial groups was lower than that of the urothelial
bladder carcinoma patients (53 vs. 60) indicating the aggressive
nature of the non-urothelial variants of bladder cancer. In
addition, 64% of the patients had urothelial carcinomas, whereas
only 24% presented with the non-urothelial variants. These
demographic data were in accordance with the changing pattern
of bladder cancer in Egypt previously reported by Felix et al. in
2008 [5], thus, highlighting the emergence and prevalence of the
transitional cell type and retraction of the non-urothelial types.
Conclusively, RFC expression can be considered as a double-
edged weapon (Figure 2). Increased RFC expression would
promote chemosensitivity to antifolates while, expanding intracel-
lular folate pool size; which may lead to acquired resistance. This
notion is further supported by the finding that loss of folate
exporters led to resistance to antifolates through an expansion of
the folate pool size [21]. Particularly, in bladder carcinomas, Rady
et al., (unpublished results) reported that BCRP (exports mono-, di-,
and triglutamates of folates) expression was decreased, whereas
MRP3, which have restricted ability to export only monoglutamate
folates, was found to be overexpressed [Unpublished work by Rady
et al. 2009]. Moreover, MRP3 was significantly higher in the
urothelial relative to the non-urothelial bladder carcinoma variant
[Unpublished work by Rady et al. 2009]. These variations in the
expression levels of antifolates efflux and influx pumps imply that
the utilization of a panel of genetic biomarkers for each tumor type
may be more appropriate for defining response to chemotherapy
rather than a single independent genetic marker.
Conclusions and Future Directions
The present study was undertaken to investigate alterations in
RFC expression among the different variants of bladder
carcinomas. RFC mRNA expression was shown to be type-
dependent but stage- and grade-independent. Although differen-
tiation between urothelial and non-urothelial bladder carcinomas
can be done by microscopic examination, our ultimate goal would
be to integrate molecular diagnostics into clinical practice.
Prospective evaluation of a panel of folate transporters (like;
RFC, BCRP, and MRP3), can predict response to antifolate
therapy, suggest new therapeutic strategies and hence, improve the
treatment outcome for individual bladder cancer patients. The
differences described between urothelial and non-urothelial
carcinomas of the bladder could reflect different etiologies and/
or risk factors. A larger study designed to provide correlations of
the extent of RFC methylation with clinicopathological charac-
teristics such as age, sex, histological grade, stage, and progression
could provide additional useful information about the etiology of
RFC altered levels of expression among different types of bladder
cancers. Other known DNA methylation targets in bladder might
also be included to see the effect of higher expression of RFC and
higher folate transport on DNA methylation.
Figure 2. RFC is a double-edged weapon. A diagram depicting the
proposed double-edged role of RFC in cancer chemotherapy. Increased
expression is predictive of antifolates (MTX) transport. At the same time,
increased expression of RFC will lead to folate pool size expansion
forcing a negative feedback inhibition on the uptake of antifolates.
doi:10.1371/journal.pone.0021820.g002
RFC Expression in Bladder Cancer
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Figure S1 RNA Quality Assessment. Agarose Gel Electro-
phoresis of total RNA minipreps. Specimens’ lanes are labeled
according to their code number assigned to them after collection.
Observing sharp bands of the 28S rRNA (4.8 kb) and 18S rRNA
(1.8 kb) was the indication for intact RNA (T82, T65, S22 and
T38). S22 and S38 contain traces of genomic DNA, however the
RFC and b-actin primers were designed to span exon/intron
junction to minimize genomic DNA amplification. T118 showed
partial degradation but the 28S and 18S bands were very faint; the
total RNA yield of T118 was only 2 mg. T107 showed degraded
RNA and was excluded from further analysis. RNA (arrows) and
DNA size markers (1031-80 bp) were included for comparison.
This image was photographed using UVIsoft image acquisition
system (Tokyo, Japan).
(TIF)
Figure S2 Melting Curve Analyses. Melting curve analysis
for demonstrating the primers’ specificity. Panel A: Dye fluores-
cence drops rapidly when the DNA melts. The melting point is
defined as the inflection point of the melting curve, which is easiest
determined as the maximum in the negative 1st derivative of the
melting curve. The dissociation curves for both the target (RFC)
and reference (ACTB) genes are shown. Each product displays a
single sharp peak indicating the specificity of the primer pairs and
absence of primer-dimers or non-specific amplification products.
NTC either didn’t record a Ct value or recorded Ct values in the
range between (35–38) which differ by more than 5cycles from the
highest Ct value recorded by the samples (not shown). The Flat
curves of the ROX passive dye indicate no spiking (not shown).
Panel B: Agarose gel electrophoresis of conventional PCR product
using reverse transcribed cDNA of one tumor sample (T42) and
reverse transcribed cDNA of the calibrator (commercially
available, normal bladder RNA, Clonetech). Single bands of the
correct sizes for RFC and the reference gene indicate the
specificity of the products.
(TIF)
Table S1 Clinical characteristics of bladder cancer
patients.
(XLS)
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